KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Change in Account Payables (2020 - 2023)

Ginkgo Bioworks Holdings' Change in Account Payables history spans 4 years, with the latest figure at -$6.7 million for Q2 2023.

  • For Q2 2023, Change in Account Payables rose 57.14% year-over-year to -$6.7 million; the TTM value through Jun 2023 reached -$18.5 million, down 217.66%, while the annual FY2025 figure was -$3.0 million, 162.71% down from the prior year.
  • Change in Account Payables reached -$6.7 million in Q2 2023 per DNA's latest filing, down from $9.7 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $26.2 million in Q1 2022 to a low of -$15.6 million in Q2 2022.
  • Average Change in Account Payables over 4 years is -$525363.6, with a median of $516000.0 recorded in 2021.
  • The largest YoY upside for Change in Account Payables was 4987.21% in 2022 against a maximum downside of 2912.4% in 2022.
  • A 4-year view of Change in Account Payables shows it stood at $4.3 million in 2020, then tumbled by 87.87% to $524000.0 in 2021, then crashed by 2912.4% to -$14.7 million in 2022, then surged by 54.63% to -$6.7 million in 2023.
  • Per Business Quant, the three most recent readings for DNA's Change in Account Payables are -$6.7 million (Q2 2023), $9.7 million (Q1 2023), and -$14.7 million (Q4 2022).